首页> 外文期刊>International heart journal >Effects of omeprazole on the antiplatelet activity of clopidogrel.
【24h】

Effects of omeprazole on the antiplatelet activity of clopidogrel.

机译:奥美拉唑对氯吡格雷抗血小板活性的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

Clopidogrel is used with aspirin as a standard combined treatment in patients with acute coronary syndrome. A proton pump inhibitor (PPI) is often administered to patients receiving antiplatelet therapy. However, PPI use with clopidogrel was recently shown to result in increased risk of major cardiovascular events when compared to clopidogrel use alone. Therefore, the aim of the present study was to evaluate the effects of omeprazole, a PPI, on the antiplatelet effect of clopidogrel.We divided 20 healthy volunteers into 2 groups (n = 10 each). Twenty-four hours after a 300 mg loading dose of clopidogrel, one group received a dosage of 75 mg/day of clopidogrel and a placebo for 14 days, followed 3 weeks later by the same protocol but with coadministration of 75 mg/day clopidogrel and 20 mg/day omeprazole instead. The other group received the same treatment but in reverse order. Antiplatelet activity was assessed in terms of the P2Y12 reaction unit (PRU) and percentage inhibition using a VerifyNow P2Y12 assay system.The PRU of the omeprazole-treated subjects was significantly higher than that of the omeprazole-untreated subjects on day 14 (281.3 +/- 54.0 versus 240.0 +/- 72.2, P = 0.048). The percentage inhibition showed a decrease after the 14-day omeprazole treatment (22.7 +/- 29.9% versus 35.1 +/- 18.7%, P = 0.014). Consequently, omeprazole reduces the antiplatelet effect of clopidogrel, suggesting that careful treatment planning is required when administering omeprazole to patients on clopidogrel therapy.
机译:氯吡格雷与阿司匹林一起作为急性冠脉综合征患者的标准联合治疗药物。质子泵抑制剂(PPI)通常用于接受抗血小板治疗的患者。但是,最近显示,与单独使用氯吡格雷相比,氯吡格雷与PPI的使用会导致发生重大心血管事件的风险增加。因此,本研究的目的是评估奥美拉唑(PPI)对氯吡格雷的抗血小板作用的影响。我们将20名健康志愿者分为两组(每组10名)。服用300毫克氯吡格雷后的24小时内,一组患者接受75毫克/天的氯吡格雷和安慰剂的治疗,持续14天,随后3周后采用相同的方案,但同时服用75毫克/天的氯吡格雷和奥美拉唑20毫克/天。另一组接受相同的治疗,但顺序相反。使用VerifyNow P2Y12分析系统根据P2Y12反应单位(PRU)和抑制百分比评估抗血小板活性。第14天,经奥美拉唑治疗的受试者的PRU显着高于未经奥美拉唑治疗的受试者的PRU(281.3 + / -54.0对240.0 +/- 72.2,P = 0.048)。奥美拉唑治疗14天后,抑制百分比降低(22.7 +/- 29.9%对35.1 +/- 18.7%,P = 0.014)。因此,奥美拉唑降低了氯吡格雷的抗血小板作用,这表明向接受氯吡格雷治疗的患者服用奥美拉唑时需要仔细的治疗计划。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号